GALECTIN THERAPEUTICS INC. Increase (Decrease) in Interest Payable, Net
GALECTIN THERAPEUTICS INC. (GALT) reported Increase (Decrease) in Interest Payable, Net of $3.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. increase (decrease) in interest payable, net for the quarter ending 2026-06-30 was $1.85M, a 24.97% increase year-over-year.
- GALECTIN THERAPEUTICS INC. increase (decrease) in interest payable, net for the quarter ending 2026-03-31 was $1.83M, a 31.07% increase year-over-year.
- GALECTIN THERAPEUTICS INC. increase (decrease) in interest payable, net for the quarter ending 2025-12-31 was $1.76M, a 27.90% increase year-over-year.
- GALECTIN THERAPEUTICS INC. increase (decrease) in interest payable, net for the quarter ending 2025-09-30 was $1.60M, a 33.33% increase year-over-year.
- GALECTIN THERAPEUTICS INC. increase (decrease) in interest payable, net for fiscal 2025 was $6.24M, a 40.43% increase from fiscal 2024.
- GALECTIN THERAPEUTICS INC. increase (decrease) in interest payable, net for fiscal 2024 was $4.44M, a 111.73% increase from fiscal 2023.
- GALECTIN THERAPEUTICS INC. increase (decrease) in interest payable, net for fiscal 2023 was $2.10M, a 236.60% increase from fiscal 2022.
- GALECTIN THERAPEUTICS INC. increase (decrease) in interest payable, net for fiscal 2022 was $623.00K, a 202.43% increase from fiscal 2021.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $3.68M 10-Q · filed 2026-08-14 | $5.43M derived: sum of 3 quarters · filed 2026-08-14 | $7.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.83M 10-Q · filed 2026-05-15 | $3.59M derived: sum of 2 quarters · filed 2026-05-15 | $5.19M derived: sum of 3 quarters · filed 2026-05-15 | $6.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.36M derived: sum of 2 quarters · filed 2026-03-31 | $4.84M derived: sum of 3 quarters · filed 2026-08-14 | $6.24M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.08M derived: sum of 2 quarters · filed 2026-08-14 | $4.48M 10-Q · filed 2025-11-14 | $5.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.88M 10-Q · filed 2026-08-14 | $4.25M derived: sum of 3 quarters · filed 2026-08-14 | $5.45M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.40M 10-Q · filed 2026-05-15 | $2.77M derived: sum of 2 quarters · filed 2026-05-15 | $3.97M derived: sum of 3 quarters · filed 2026-05-15 | $4.99M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.58M derived: sum of 2 quarters · filed 2026-03-31 | $3.60M derived: sum of 3 quarters · filed 2026-03-31 | $4.44M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.22M derived: sum of 2 quarters · filed 2025-11-14 | $3.07M 10-Q · filed 2025-11-14 | $3.73M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.86M 10-Q · filed 2025-08-14 | $2.52M derived: sum of 3 quarters · filed 2025-08-14 | $3.16M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $843.00K 10-Q · filed 2025-05-15 | $1.50M derived: sum of 2 quarters · filed 2025-05-15 | $2.14M derived: sum of 3 quarters · filed 2025-05-15 | $2.62M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $658.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.30M derived: sum of 2 quarters · filed 2025-03-31 | $1.78M derived: sum of 3 quarters · filed 2025-03-31 | $2.10M 10-K · filed 2025-03-31 |
| 2023-09-30 | $641.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.12M derived: sum of 2 quarters · filed 2024-11-14 | $1.44M 10-Q · filed 2024-11-14 | $1.61M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $482.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $798.00K 10-Q · filed 2024-08-13 | $973.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.12M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $316.00K 10-Q · filed 2024-05-15 | $491.00K derived: sum of 2 quarters · filed 2024-05-15 | $641.00K derived: sum of 3 quarters · filed 2024-05-15 | $792.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $325.00K derived: sum of 2 quarters · filed 2024-03-29 | $476.00K derived: sum of 3 quarters · filed 2024-03-29 | $623.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $301.00K derived: sum of 2 quarters · filed 2023-11-13 | $448.00K 10-Q · filed 2023-11-13 | $555.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $298.00K 10-Q · filed 2023-08-14 | $405.00K derived: sum of 3 quarters · filed 2023-08-14 | $463.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $147.00K 10-Q · filed 2023-05-15 | $254.00K derived: sum of 2 quarters · filed 2023-05-15 | $312.00K derived: sum of 3 quarters · filed 2023-05-15 | $353.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $165.00K derived: sum of 2 quarters · filed 2023-03-30 | $206.00K derived: sum of 3 quarters · filed 2023-03-30 | $206.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $99.00K derived: sum of 2 quarters · filed 2022-11-14 | $99.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $41.00K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |